Tumor cell–derived IL-15 was required for tumor growth suppression enhancement and CD8+T cell regulation mediated by Piezo2 deficiency after IR treatment. Related to Fig. 3. (A) MFI summary of IL-15 expression in CD45+ or CD45− cells in indicated MC38 tumors was represented from three independent experiments (n = 5–6 mice per group). (B) MFI summary of IL-15 expression in indicated immune cells was shown from two independent experiments (n = 6–9 mice per group). (C) The knockdown efficiency of IL-15 expression in MC38 cells was shown in two independent experiments. (D) Representative data and quantification of the percentage of TCF-1+ in exhausted CD8+ T cells within irradiated WT, IL-15−/−, Piezo2−/−, and Piezo2−/−IL-15−/− tumors were shown from two independent experiments (n = 3–5 mice per group). (E) Representative data and quantification of the percentage of IL-15Rα+ in CD8+ T cells from WT and Piezo2−/− MC38 tumors on day 7 and 14 after IR treatment were shown from three independent experiments (n = 4–5 mice per group). (F) Quantification of the percentage of IL-15Rα+ in CD8+ T cells from DLNs of WT and Piezo2−/− MC38 tumor–established mice on day 5 after IR treatment was shown from two independent experiments (n = 5–6 mice per group). (G–I) The positive relevance of IL-15Rα with IFN-γ (G), Ki-67 (H), and TCF-1 (I) in tumor-infiltrating CD8+ T cells was shown by two independent experiments (n = 4–6 mice per group). (J) MFI summary of IL-15Rα expression in indicated immune cells within tumors was shown by independent three experiments (n = 5–6 mice per group). (K) The expression of p-STAT5 in CD8+ T cells from irradiated tumors on days 7 and 14 upon radiation treatment was represented by two independent experiments (n = 3–7 mice per group). Data were represented as means ± SEM. The comparisons of two datasets were calculated by paired Student’s t test (A and G–I). Statistical analysis was performed by one-way ANOVA with multiple comparison tests (B, D–F, J, and K). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, ns, no significant difference. Source data are available for this figure: SourceData FS3.
Figure S3.

Tumor cell–derived IL-15 was required for tumor growth suppression enhancement and CD8 + T cell regulation mediated by Piezo2 deficiency after IR treatment. Related to Fig. 3. (A) MFI summary of IL-15 expression in CD45+ or CD45− cells in indicated MC38 tumors was represented from three independent experiments (n = 5–6 mice per group). (B) MFI summary of IL-15 expression in indicated immune cells was shown from two independent experiments (n = 6–9 mice per group). (C) The knockdown efficiency of IL-15 expression in MC38 cells was shown in two independent experiments. (D) Representative data and quantification of the percentage of TCF-1+ in exhausted CD8+ T cells within irradiated WT, IL-15−/−, Piezo2−/−, and Piezo2−/−IL-15−/− tumors were shown from two independent experiments (n = 3–5 mice per group). (E) Representative data and quantification of the percentage of IL-15Rα+ in CD8+ T cells from WT and Piezo2−/− MC38 tumors on day 7 and 14 after IR treatment were shown from three independent experiments (n = 4–5 mice per group). (F) Quantification of the percentage of IL-15Rα+ in CD8+ T cells from DLNs of WT and Piezo2−/− MC38 tumor–established mice on day 5 after IR treatment was shown from two independent experiments (n = 5–6 mice per group). (G–I) The positive relevance of IL-15Rα with IFN-γ (G), Ki-67 (H), and TCF-1 (I) in tumor-infiltrating CD8+ T cells was shown by two independent experiments (n = 4–6 mice per group). (J) MFI summary of IL-15Rα expression in indicated immune cells within tumors was shown by independent three experiments (n = 5–6 mice per group). (K) The expression of p-STAT5 in CD8+ T cells from irradiated tumors on days 7 and 14 upon radiation treatment was represented by two independent experiments (n = 3–7 mice per group). Data were represented as means ± SEM. The comparisons of two datasets were calculated by paired Student’s t test (A and G–I). Statistical analysis was performed by one-way ANOVA with multiple comparison tests (B, D–F, J, and K). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, ns, no significant difference. Source data are available for this figure: SourceData FS3.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal